Qiyou Li

Qiyou Li

Auto-generated profile, based on publicly available information

Qiyou Li

Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
BBBaishijiao Bian
Baishijiao Bian
CZCongjian Zhao
Congjian Zhao
XHXiangyu He
Xiangyu He
YGYu Gong
Yu Gong
CRChunge Ren
Chunge Ren
ZYZheng Qin Yin
Zheng Qin Yin
Retinal degeneration (RD) is one of the most common causes of visual impairment and blindness and is characterized by progressive degeneration of photoreceptors. Transplantation of neural stem/progenitor cells (NPCs) is a promising treatment for RD, although the mechanisms underlying the efficacy remain unclear. Accumulated evidence supports the notion that paracrine effects of transplanted stem cells is likely the major approach to rescuing early degeneration, rather than cell replacement. NPC‐derived exosomes (NPC‐exos), a type of extracellular vesicles (EVs) released from NPCs, are thought to carry functional molecules to recipient cells and play therapeutic roles. In present study, we found that grafted human NPCs (hNPCs) secreted EVs and exosomes in the subretinal space (SRS) of RCS rats, an RD model. And direct administration of mouse neural progenitor cell‐derived exosomes (mNPC‐exos) delayed photoreceptor degeneration, preserved visual function, prevented thinning of the outer nuclear layer (ONL), and decreased apoptosis of photoreceptors in RCS rats. Mechanistically, mNPC‐exos were specifically internalized by retinal microglia and suppressed their activation in vitro and in vivo . RNA sequencing and miRNA profiling revealed a set of 17 miRNAs contained in mNPC‐exos that markedly inhibited inflammatory signal pathways by targeting TNF‐α, IL‐1β, and COX‐2 in activated microglia. The exosomes derived from hNPC (hNPC‐exos) contained similar miRNAs to mNPC‐exos that inhibited microglial activation. We demonstrated that NPC‐exos markedly suppressed microglial activation to protect photoreceptors from apoptosis, suggesting that NPC‐exos and their contents may be the mechanism of stem cell therapy for treating RD.

29 December 2022 in Science of The Total Environment
Verified
Journal Article
Closed access
Yang LingYang Ling
Yang Ling
JZJiao Zou
Jiao Zou
ZZZhenle Zang
Zhenle Zang
LWLiuyongwei Wang
Liuyongwei Wang
ZDZhulin Du
Zhulin Du
XFXiaotang Fan
Xiaotang Fan

29 November 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MCMin Chen
Min Chen
CRChunge Ren
Chunge Ren
BRBangqi Ren
Bangqi Ren
YFYajie Fang
Yajie Fang
QLQiyou Li
Qiyou Li
YLYong Liu
Yong Liu
Retinal degeneration is a leading cause of irreversible vision impairment and blindness worldwide. Previous studies indicate that subretinal injection of human retinal progenitor cells (hRPCs) can delay the progression of retinal degeneration, preserve retinal function, and protect photoreceptor cells from death, albeit the mechanism is not well understood. In this study, small extracellular vesicles derived from hRPCs (hRPC-sEVs) were injected into the subretinal space of retinal dystrophic RCS rats. We find that hRPC-sEVs significantly preserve the function of retina and thickness of the outer nuclear layer (ONL), reduce the apoptosis of photoreceptors in the ONL, and suppress the inflammatory response in the retina of RCS rats. In vitro, we have shown that hRPC-sEV treatment could significantly reserve the low-glucose preconditioned apoptosis of photoreceptors and reduce the expression of pro-inflammatory cytokines in microglia. Pathway analysis predicted the target genes of hRPC-sEV microRNAs involved in inflammation related biological processes and significantly enriched in processes autophagy, signal release, regulation of neuron death, and cell cycle. Collectively, our study suggests that hRPC-sEVs might be a favorable agent to delay retinal degeneration and highlights as a new paradigm for cell-free therapy.

1 January 2019 in Development
Verified
Journal Article
Closed access
PDF file
YGYu Gong
Yu Gong
XHXiangyu He
Xiangyu He
QLQiyou Li
Qiyou Li
JHJuncai He
Juncai He
BBBaishijiao Bian
Baishijiao Bian
ZYZheng Qin Yin
Zheng Qin Yin
The stem cell factor receptor (SCFR) has been demonstrated to be expressed in the neural retina of mice, rat, and human for decades. Previous reports indicate that SCFR correlates with glia differentiation of late retinal progenitor cells (RPCs), retinal vasculogenesis, and homeostasis of the blood-retinal barrier. However, the role of SCF/SCFR signaling in the growth and development of the neural retina (NR), especially in the early embryonic stage, remains poorly understood. Here we show that the SCF/SCFR signaling orchestrates invagination of the human embryonic stem cell (hESC)-derived NR via regulation of cell cycle progression, cytoskeleton dynamic, and apical constriction of RPCs in the ciliary marginal zone (CMZ). Furthermore, activation of SCF/SCFR signaling promotes neurogenesis in the central-most NR via accelerating the migration of immature ganglion cells and repressing apoptosis. Our study reveals an unreported role of SCF/SCFR signaling in controlling ciliary marginal cellular behaviors during early morphogenesis and neurogenesis of the human embryonic NR, providing a new potential therapeutic target for human congenital eye diseases such as anophthalmia, microphthalmia, and congenital high myopia.

29 July 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
CRChunge Ren
Chunge Ren
MCMin Chen
Min Chen
BRBangqi Ren
Bangqi Ren
YZYuxiao Zeng
Yuxiao Zeng
QTQiang Tan
Qiang Tan
YLYong Liu
Yong Liu
JOURNAL/nrgr/04.03/01300535-202602000-00050/figure1/v/2026-04-22T115157Z/r/image-tiff Our previous study demonstrated that combined transplantation of bone marrow mesenchymal stem cells and retinal progenitor cells in rats has therapeutic effects on retinal degeneration that are superior to transplantation of retinal progenitor cells alone. Bone marrow mesenchymal stem cells regulate and interact with various cells in the retinal microenvironment by secreting neurotrophic factors and extracellular vesicles. Small extracellular vesicles derived from bone marrow mesenchymal stem cells, which offer low immunogenicity, minimal tumorigenic risk, and ease of transportation, have been utilized in the treatment of various neurological diseases. These vesicles exhibit various activities, including anti-inflammatory actions, promotion of tissue repair, and immune regulation. Therefore, novel strategies using human retinal progenitor cells combined with bone marrow mesenchymal stem cell–derived small extracellular vesicles may represent an innovation in stem cell therapy for retinal degeneration. In this study, we developed such an approach utilizing retinal progenitor cells combined with bone marrow mesenchymal stem cell–derived small extracellular vesicles to treat retinal degeneration in Royal College of Surgeons rats, a genetic model of retinal degeneration. Our findings revealed that the combination of bone marrow mesenchymal stem cell-derived small extracellular vesicles and retinal progenitor cells significantly improved visual function in these rats. The addition of bone marrow mesenchymal stem cell–derived small extracellular vesicles as adjuvants to stem cell transplantation with retinal progenitor cells enhanced the survival, migration, and differentiation of the exogenous retinal progenitor cells. Concurrently, these small extracellular vesicles inhibited the activation of regional microglia, promoted the migration of transplanted retinal progenitor cells to the inner nuclear layer of the retina, and facilitated their differentiation into photoreceptors and bipolar cells. These findings suggest that bone marrow mesenchymal stem cell–derived small extracellular vesicles potentiate the therapeutic efficacy of retinal progenitor cells in retinal degeneration by promoting their survival and differentiation.

18 August 2021 in International Journal of Ophthalmology
Verified
Journal Article
Open access
HXHao-Jue Xu
Hao-Jue Xu
QLQi-You Li
Qi-You Li
TZTing Zou
Ting Zou
ZYZheng-Qin Yin
Zheng-Qin Yin
AIM: To explore the temporal mitochondrial characteristics of retinal pigment epithelium (RPE) cells obtained from human embryonic stem cells (hESC)-derived retinal organoids (hEROs-RPE), to verify the optimal period for using hEROs-RPE as donor cells from the aspect of mitochondria and to optimize RPE cell-based therapeutic strategies for age-related macular degeneration (AMD). METHODS: RPE cells were obtained from hEROs and from spontaneous differentiation (SD-RPE). The mitochondrial characteristics were analyzed every 20d from day 60 to 160. Mitochondrial quantity was measured by MitoTracker Green staining. Transmission electron microscopy (TEM) was adopted to assess the morphological features of the mitochondria, including their distribution, length, and cristae. Mitochondrial membrane potentials (MMPs) were determined by JC-1 staining and evaluated by flow cytometry, reactive oxygen species (ROS) levels were evaluated by flow cytometry, and adenosine triphosphate (ATP) levels were measured by a luminometer. Differences between two groups were analyzed by the independent-samples t-test, and comparisons among multiple groups were made using one-way ANOVA or Kruskal-Wallis H test when equal variance was not assumed. RESULTS: hEROs-RPE and SD-RPE cells from day 60 to 160 were successfully differentiated from hESCs and expressed RPE markers (Pax6, MITF, Bestrophin-1, RPE65, Cralbp). RPE features, including a cobblestone-like morphology with tight junctions (ZO-1), pigments and microvilli, were also observed in both hEROs-RPE and SD-RPE cells. The mitochondrial quantities of hEROs-RPE and SD-RPE cells both peaked at day 80. However, the cristae of hEROs-RPE mitochondria were less mature and abundant than those of SD-RPE mitochondria at day 80, with hEROs-RPE mitochondria becoming mature at day 100. Both hEROs-RPE and SD-RPE cells showed low ROS levels from day 100 to 140 and maintained a normal MMP during this period. However, hEROs-RPE mitochondria maintained a longer time to produce high levels of ATP (from day 120 to 140) than SD-RPE cells (only day 120). CONCLUSION: hEROs-RPE mitochondria develop more slowly and maintain a longer time to supply high-level energy than SD-RPE mitochondria. From the mitochondrial perspective, hEROs-RPE cells from day 100 to 140 are an optimal cell source for treating AMD.